Preeclampsia Biomarker Test is a clinical support utility for obstetricians and prenatal care providers to interpret sFlt-1/PlGF biomarker ratios on iOS.
The App DNA
What makes this app unique?
The tool removes the need for manual reference-range lookups during high-pressure clinical assessments, reducing the cognitive load on providers evaluating suspected preeclampsia.
For Qualified healthcare professionals including obstetricians, maternal-fetal medicine specialists, and prenatal care providers.
What does it look like?
Key features
Calculates testing criteria based on gestational age and clinical presentation.
Provides actionable guidance for interpreting biomarker test results against clinical reference ranges.
Performs all clinical calculations on the device without cloud transmission or data storage.
How much does it cost?
Distributed as a free utility with no monetization or subscription tiers.
Velocity
Maintenance developmentUX improvementsShow more...
With only one release in the observed window and 219 days since the last update, the app is in a maintenance phase. Development activity is limited to minor clinical reference updates and disclaimers rather than functional improvements or new features. The current cadence suggests a stable, low-touch product lifecycle focused on regulatory compliance rather than active feature expansion.
Who built it?
User Sentiment
What do users think recently?
Recent user voice shows a thrilled sentiment. Users appreciate the clear and simple interface allows users to quickly identify eligibility criteria for clinical testing.
How are ratings & reviews evolving?
What users say, by theme
- The clear and simple interface allows users to quickly identify eligibility criteria for clinical testing
1 of 1 recent reviews analyzed · limited sample
Read the full review analysisCompetition
Competitive landscape for Preeclampsia Biomarker Test
How's the Medical market?
Preeclampsia Biomarker Test occupies a niche utility space in the Medical category, maintaining a 5.0 rating across 8 ratings. The lack of recent feature updates relative to its 7-month development gap limits its ability to capture broader clinical workflow market share.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for Preeclampsia Biomarker Test
Where is it heading?
The clinical decision-support market is shifting toward integrated electronic health record workflows, which places Preeclampsia Biomarker Test at a disadvantage as a standalone utility. The app must prioritize algorithm currency to remain a trusted reference tool for obstetricians.
- The 7-month development gap indicates a maintenance-only posture, which limits the app's ability to adapt to new clinical research.
The SWOT
- Local-only processing removes data-privacy barriers for hospital IT compliance
- Integration of automated reporting workflows could reduce manual entry time for clinicians
Next best moves
Audit clinical algorithms against the latest peer-reviewed guidelines because the 7-month update gap risks medical obsolescence → maintain diagnostic trust
The counter-intuitive read
The app's lack of cloud connectivity is a feature, not a bug…
Read the full takeSince the last report: The app's competitive posture has shifted from a secure, niche utility to a vulnerable product facing potential medical obsolescence due to a seven-month development gap. The analysis now prioritizes the risk of outdated clinical guidance over the previous focus on international market expansion.
Bottom line
Preeclampsia Biomarker Test provides a stable, privacy-focused reference utility for clinicians, but the lack of active development risks its relevance as clinical guidelines evolve. Maintaining medical accuracy is the primary lever to defend its position against more integrated clinical platforms.
Unlock 1 critical friction, 1 market threat and the analyst’s take.
Access the full report for freeSources
- [1] App Store, source
Report last updated